复方丹参液对大鼠失血性休克合并凝血功能紊乱的治疗作用

为了观察大鼠失血性休克过程中凝血因子的变化及肝素、复方丹参注射液对凝血因子变化的影响,探讨复方丹参注射液对凝血功能紊乱的治疗作用,制作了失血性休克大鼠模型。将40只SD大鼠随机分为假手术组、休克组、复方丹参液组及肝素组,每组10只。检测各组休克后2、4、6小时血浆可溶性纤维蛋白单体复合物(SFMC)、血栓调节蛋白(TM)、抗凝血酶Ⅲ(ATⅢ)、D二聚体(DD)、组织型纤溶酶原激活剂(tPA)、纤溶酶原激活物抑制剂(PAI)变化及活化部分凝血活酶时间(APTT);比较肝素组与复方丹参液组出血并发症的发生率。研究结果表明:大鼠休克组血浆SFMC、DD水平明显高,于而ATⅢ明显低于其他3组(P<0.001),其他3组间比较,无显著性差异(P>0.05)。休克组、肝素组血浆TM水平明显增加(P<0.001),复方丹参组与假手术组间相比无显著性差异。休克组大鼠于休克2小时血浆tPA、DD水平明显升高,于休克4小时PAI达到高峰(P<0.001),而tPA水平有所下降。于休克6小时,血浆PAI水平下降,tPA继续降低,但PAI、DD尚维持于较高水平。肝素组血浆DD水平降低、tPA高于休克组、PAI无显著性不同。丹参组大鼠血浆tPA、PAI、DD均低于休克组,但均在正常范围内。休克组大鼠APTT进行性延长,至休克6小时达到高峰,平均59.7±11.86秒。肝素组APTT平均61.5±5.79秒

Therapeutic Effect of Compound Danshen Solution on Hemorrhagic Shock Combined with Coagulopathy in Rats

To investigate the effects of complex danshen solution and heparin on the changes of blood coagulation factors in rats with hemorrhagic shock, and to explore the therapy of coagulopathy by compound danshen solution, the rat model of hemorrhagic shock was set up, 40 SD rats were randomized into four groups: sham operation, shock, compound danshen solution and heparin groups, each group was composed of 10 SD rats. Plasma SFMC, TM, ATIII, D-D, t-PA, PAI levels and APTT were detected, incidences of bleeding complications between heparin and danshen group were compared. The results showed that plasma SFMC, D-D levels in shock group were higher but ATIII level in shock group was lower than that in sham operation group, compound danshen solution group and heparin group (P < 0.001), TM levels obviously increased in shock group and heparin group (P < 0.001). There was no significant difference between compound danshen solution and sham-operation groups. Plasma t-PA, D-D levels obviously increased after shock for 2 hours, PAI level reached the peak after shock for 4 hours, but t-PA decreased. After shock for 6 hours, plasma PAI descended, t-PA continually drop in, but PAI and D-D remained in higher levels. Plasma D-D level in heparin group was lower than that in shock group, t-PA level was higher than that in shock group, but there was no significant difference between in heparin and shock groups. Plasma t-PA, PAI and D-D levels in compound danshen solution group were lower than that in shock group. APTT of danshen group was lower than that of shock group and heparin group. Bleeding incidences was 30% in heparin group and 0% in danshen group, respectively. It is concluded that compound danshen solution may used to treat hypercoagulation and hyperfibrinolysis. In comparsion with heparin, danshen posses-ses advantages of safety with less bleeding complication and needs not tight monitor.